Clinical trial NCT03129126: The Safety, Tolerability and Efficacy of LP-10 in Subjects With Refractory Moderate to Severe Hemorrhagic Cystitis
Official title: A Multicenter, Dose-Ranging Trial Evaluating the Safety, Tolerability and Efficacy of LP-10 in Subjects With Refractory Moderate to Severe Hemorrhagic Cystitis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Hemorrhagic Cystitis
Lead sponsor: Lipella Pharmaceuticals, Inc.
Sponsor class: INDUSTRY
First posted: 2017-04-26
Enrollment: 13
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SEQUENTIAL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to assess the safety and tolerability of three doses of LP-10 (intravesical tacrolimus). Twelve subjects meeting the inclusion and exclusion criteria will be enrolled and treated in a prospective and multi-center trial with LP-10. The proposed trial will recruit 12 subjects in a dose-escalation trial where 4 subjects will be allocated into each one of three groups.

Detailed description: This is a multi-center, dose-ranging study including male and female subjects with refractory moderate to severe hemorrhagic cystitis as determined by a physician. A total of up to 12 subjects are anticipated and will be enrolled in study sites in the United States. Enrollment is expected to be completed within one year of initiating the study. The proposed trial will recruit 12 subjects in a dose-escalation trial where 4 subjects will be allocated into each one of three groups.

Eligibility criteria: Inclusion Criteria:

Males and females, at least 18 years

* History of sterile moderate to severe HC (Grade 2-4) for at least 3 months documented in the medical record with at least 1 episode of macroscopic hematuria with or without clot
* Previous use of medications and/or treatment(s) for HC without success
* Patients of child-bearing capability agree to use a reliable form of birth control (condoms and/or oral contraceptives) during the course of instillation therapy and for 1 week thereafter
* Willing and capable of understanding and complying with all requirements of the protocol, including proper completion of the 3 day Hemorrhagic Cystitis Diary (HC Diary) and self-administered questionnaires

Exclusion Criteria:

* History of interstitial cystitis/painful bladder syndrome
* HC due to infection (bacterial, viral or fungal)
* Vesicoureteral reflux disease based on cystogram within past 12 months
* Subject is currently or has previously participated in another therapeutic or device study within 3 months of screening and has not returned to baseline
* Pregnant or lactating
* History of bleeding diathesis or active bleeding peptic ulcer disease
* Life expectancy less than 12 months
* PSA \> 10.0 ng/dl (measured within the last 3 months)
* Known allergy to liposomes and/or egg yolk and/or tacrolimus
* Urinary retention requiring daily catheterization
* Previous augmentation cystoplasty
* Subjects currently taking prescribed treatment for HC will be able to continue the treatment throughout the course of the study. If the patient cannot be maintained on a stable dose of the medication(s) throughout the treatment and follow-up period they will be excluded
* Subject with history of intravesical treatment(s) within 1 week prior to Study Visit 1
* Sacral and/or pudendal nerve neuromodulation device (Interstim) within the last 6 months. Subjects would not be excluded if they had Interstim greater than 6 months ago and is on a stable setting.
* Evidence of renal impairment (creatinine \> two times the upper limit of normal at Visit 1), hepatic impairment (AST or ALT \> three times the upper limit of normal at Visit 1), clinically significant cardiovascular, respiratory, or psychiatric diseases per investigator's judgment
* Post-void residual (PVR) urine volume of \> 150 mL at screening
* The presence of any clinically significant systemic disease or condition that in the opinion of the investigator would make the patient unsuitable for the study

Primary outcomes:
measure: Patient Reported Mean episodes of visible blood
timeFrame: At every patient visit, up to 2 weeks following initial treatment
Secondary outcomes:
measure: Urine Dipstick Mean episodes of Visible Blood
timeFrame: At every patient visit, up to 2 weeks following initial treatment
measure: Mean urine hemoglobin concentration
timeFrame: At every patient visit, up to 2 weeks following initial treatment
measure: Urine analysis with microscopy
timeFrame: At every patient visit, up to 2 weeks following initial treatment
measure: Whole blood Add to dictionary levels
timeFrame: At every patient visit, up to 2 weeks following initial treatment
measure: Blood chemistry and liver function test
timeFrame: At every patient visit, up to 2 weeks following initial treatment
measure: Patient Reported Global Response Assessment Survey Score
timeFrame: At every patient visit, up to 2 weeks following initial treatment
measure: Patient Reported Urinary frequency
timeFrame: At every patient visit, up to 2 weeks following initial treatment
measure: Bladder Cystoscopy
timeFrame: At initial treatment and on final patient visit, up to 2 weeks following initial treatment
measure: Patient Reported Health Related Quality of Life Survey Score
timeFrame: At every patient visit, up to 2 weeks following initial treatment
measure: Post void residual urine volume
timeFrame: At every patient visit, up to 2 weeks following initial treatment
measure: Patient Reported Pain and Urgency
timeFrame: At every patient visit, up to 2 weeks following initial treatment
measure: Incidence of Treatment-Emergent Adverse Events
timeFrame: At every patient visit, up to 2 weeks following initial treatment
Other outcomes:
Locations:
city: Tucson
country: United States
facility: University of Arizona
state: Arizona
city: San Francisco
country: United States
facility: University of California San Francisco
state: California
city: Atlanta
country: United States
facility: Emory University
state: Georgia
city: Troy
country: United States
facility: Michigan Institute of Urology
state: Michigan
city: Poughkeepsie
country: United States
facility: Premier Medical Group
state: New York
city: Philadelphia
country: United States
facility: Temple University
state: Pennsylvania
city: Pittsburgh
country: United States
facility: Allegheny Health Network Research Institute
state: Pennsylvania
city: Nashville
country: United States
facility: Vanderbilt University Medical Center
state: Tennessee
city: Houston
country: United States
facility: Baylor College of Medicine
state: Texas
Study officials:
References: